HER2, pyrotinib + pertuzumab/trastuzumab

Phase 2Monoclonal antibody

HER2, pyrotinib + pertuzumab/trastuzumab is one of 21 small molecule programs targeting Salivary Gland Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Salivary Gland CarcinomaActive, not recruiting

Salivary Gland CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

30 competitors in Salivary Gland Carcinoma

#DrugCompanyPhaseTrials

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Opdivo

2 3

Keytruda

Merck & Co.

Phase 2

1 4

Votrient

Novartis

Phase 2

1 5

Nubeqa

Bayer

Phase 2

1 6

Zoladex

AstraZeneca

Phase 2

1 7

Padcev

Pfizer

Phase 2

1 8

Erleada

Paraplatin

2 10

Taxotere

AAvyxa

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Salivary Gland Carcinoma

NCT06145308

Clinical

Trials by Indication[1]

Salivary Gland Carcinoma1 trial

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting·PPeking Union Medical College·Phase 2·NCT06145308·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HER2, pyrotinib + pertuzumab/trastuzumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HER2, pyrotinib + pertuzumab/trastuzumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HER2, pyrotinib + pertuzumab/trastuzumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: PPeking Union Medical College

HER2, pyrotinib + pertuzumab/trastuzumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Salivary Gland Carcinoma1 trial

References

Drug Info

Quick Facts

Related News